Penumbra's revenue growth has decelerated to 14.9% in 2026Q2 from 22.1% in 2025Q4, while operating margin contracted to 10.5% from 15.4% over the same period, reflecting competitive pressures and rising SG&A costs. The company maintains a healthy balance sheet...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth decelerated to 14.9% in 2026Q2, while gross margin remained resilient at 67.9%, but operating margin contracted to 10.5% due to SG&A rising 24% year-over-year.
Penumbra has a competitive advantage in thrombectomy technology, which is a key driver of its growth and market position.
The company is capitalizing on growing international demand for its medical devices, further boosting its revenue potential.
Penumbra's stock has risen significantly, reflecting the successful execution of its growth strategy and bullish thesis.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.88-24.1% vs $1.16 | $390M+0.1% vs $390M |
Q2 2026 May 6, 2026 | $0.82-21.2% vs $1.04 | $375M+1.2% vs $370M |
Q1 2026 Feb 25, 2026 | $1.18+6.3% vs $1.11 | $385M+6.5% vs $362M |
Q4 2025 Nov 5, 2025 | $0.97+4.4% vs $0.93 | $355M+4.0% vs $341M |
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Penumbra, Inc. (NYSE: PEN - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $321.74 and traded as low as $318.14. Penumbra shares last traded at $318.7630, with a volume of 186,317 shares changing hands. Wall Street Analyst Weigh In
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.
Benchmark PEN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Penumbra, Inc. (PEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $317.55 | $12.49B | 70.25 | 17.5% | 12.66% | 13.78% | — | |
| $391.95 | $138.47B | 49.80 | 20.51% | 28.45% | 17.71% | — | |
| $14.94 | $1.73B | -12.25 | 8.28% | -21.25% | -44% | — | |
| $23.46 | $3.82B | 83.79 | 8.32% | 3.33% | 4.1% | — | |
| $20.50 | $1.51B | 6.21 | 18.52% | 80.56% | 30.03% | — | |
| $275.43 | $105.59B | 32.79 | 11.16% | 14.43% | 16.36% | — |
Penumbra, Inc. (PEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Penumbra, Inc. (PEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 22, 2026·SEC
May 7, 2026·SEC
Get notified when PEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Penumbra, Inc. (PEN) stock FAQ — growth, dividends, profitability & financials explained
Penumbra, Inc. (PEN) reported $1.50B in revenue for fiscal year 2025. This represents a 1594% increase from $88.8M in 2013.
Penumbra, Inc. (PEN) grew revenue by 17.5% over the past year. This is strong growth.
Yes, Penumbra, Inc. (PEN) is profitable, generating $160.6M in net income for fiscal year 2025 (12.7% net margin).
Penumbra, Inc. (PEN) has a return on equity (ROE) of 13.8%. This is reasonable for most industries.
Penumbra, Inc. (PEN) generated $215.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
